News

PANTHERx Rare Partners with Chiesi to Enhance Acromegaly Care

PANTHERx Rare Partners with Chiesi to Enhance Acromegaly Care

PANTHERx Rare Partners with Chiesi for MYCAPSSA® Distribution

PANTHERx Rare has been appointed by Chiesi as the exclusive specialty pharmacy responsible for distributing MYCAPSSA® (octreotide). This exciting collaboration is designed to enhance patient access to much-needed medications for those living with acromegaly, a rare endocrine disorder.

Understanding Acromegaly and MYCAPSSA®

MYCAPSSA® serves as a vital oral somatostatin analog (SSA) intended for the long-term maintenance treatment of acromegaly patients who have previously responded well to octreotide or lanreotide injections. SSAs are crucial in regulating the production of growth hormones that are often overproduced in individuals with acromegaly.

Acromegaly is characterized by the excessive release of growth hormone from the pituitary gland, frequently triggered by a benign tumor known as a pituitary adenoma. The symptoms can significantly impact a person’s quality of life, manifesting in ways such as enlarged extremities, facial changes, and various systemic complications including type 2 diabetes and heart issues.

PANTHERx Rare’s Mission

“We are thrilled to partner with Chiesi to distribute MYCAPSSA® and extend our support to those affected by acromegaly,” states Bansi Nagji, CEO of PANTHERx Rare. “Our commitment is unwavering—standing shoulder to shoulder with individuals and families coping with rare diseases. Many within the acromegaly community encounter barriers to accessing treatment, and we’re privileged to overcome those challenges together.”

About PANTHERx Rare

PANTHERx Rare is a specialty pharmacy that zeroes in on serving those with rare and orphan diseases. They not only distribute essential medications but also provide necessary access and support services for those who require it most. For this reason, it is aptly known as The Rare Disease Pharmacy®.

PANTHERx has earned multiple accolades, including accreditation from recognized bodies for its commitment to orphan drugs and its excellence in serving patients with rare diseases. They’ve also claimed the prestigious MMIT Patient Choice Award for eight consecutive years, most recently in 2025. PANTHERx is located in Pittsburgh and has the necessary licensure to operate across all 50 states and U.S. territories.

Innovation at Chiesi Global Rare Diseases

Chiesi Global Rare Diseases operates as part of the broader Chiesi Group, focusing on delivering innovative therapies for individuals affected by rare conditions. This family-owned business strives to create a more equitable healthcare environment, ensuring treatments are accessible to all, thereby enriching the lives of patients worldwide.

Safety and Efficacy of MYCAPSSA®

MYCAPSSA® is prescribed specifically for patients with acromegaly who have successfully tolerated previous octreotide or lanreotide treatments. However, it’s important to be aware of contraindications such as hypersensitivity reactions to the medication.

Patients receiving MYCAPSSA® must be monitored for potential complications, including gallbladder issues and changes in blood sugar levels. Its most common adverse reactions include nausea, diarrhea, and headache, which are crucial for healthcare providers to manage promptly.

For more comprehensive safety information, patients should always consult the prescribing guidelines provided with MYCAPSSA®.

Frequently Asked Questions

What is acromegaly?

Acromegaly is a hormonal disorder resulting from excess growth hormone, leading to enlarged extremities and various health complications.

What role does MYCAPSSA® play in treating acromegaly?

MYCAPSSA® helps manage acromegaly in patients who have responded well to injectable therapies, promoting better long-term outcomes.

How does PANTHERx Rare support patients?

PANTHERx Rare provides not only medication distribution but also comprehensive support and resources for patients affected by rare diseases.

What are common side effects of MYCAPSSA®?

Common side effects include nausea, diarrhea, and headaches. Ongoing monitoring is essential for managing these effects.

Where is PANTHERx Rare located?

PANTHERx Rare is headquartered in Pittsburgh and is accredited to operate in all U.S. states and territories.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CPSC's Management Overhaul: Progress or Just Polishing?

Updated Category News Views 192

The Tangled Web of Bureaucracy Ah, the Consumer Product Safety Commission—CPSC for short. It's like the Secretariat of product safety, but often knee-deep in old problems. Over the years, hearing about their challenges is like flipping through a well-worn playbook. But now, the talk is all about a fresh page under Acting Chairman Peter A. Feldman. The watchdog in...

Continue Reading
Centerspace Sale Faces Scrutiny Amid Investor Concerns

Updated Category News Views 40

Potential Undervaluation Looms Large over Centerspace Sale On a crisp October day, the saga of Centerspace's proposed sale to Independence Realty Trust (NYSE: IRT) is stirring the pot. Charles C. Foti, Jr., Esq., and the law firm Kahn Swick & Foti, LLC are throwing a wrench into the works, questioning the soundness of the whole shebang. The deal, valued at 3.800 shares of...

Continue Reading
Philips’ Beauty Tech Trends Promise Intimacy by 2027

Updated Category News Views 66

Beauty Tech Takes a Personal Turn It's 2026, and in the beauty industry, folks are trading flashy for the intimate and intelligent. Philips, that stalwart of tech innovation, is waving the banner, revealing three beauty trends we can't ignore if we plan to keep up with the times. The Rise of Intelligent Guidance First off, everyone and their dog seems to ask how tech is...

Continue Reading
BETR Faces Shareholder Suit After Plummeting Stock

Updated Category News Views 29

Better Home & Finance Navigates Turbulent Waters Not every day the news comes up smelling of roses, and that's putting it lightly for Better Home & Finance, trading as NASDAQ: BETR. When you're talking about a splash that sends shockwaves, losing over 28% of your stock value on a single trading day is one whale of a splash indeed. The Numbers That Shook the Waters It's no...

Continue Reading
Beer B Que Music Festival: Hip-Hop, Dancehall & Brews

Updated Category News Views 31

A Melody and Brew-Infused South Florida Celebration Boy, if festivals were stocks, I'd have bought into the Beer B Que Music Festival years ago. This event, rolling into its seventh year, isn't just another line-up of artists—it feels like a genuine cultural reunion for folks in South Florida. You throw in some heavyweight names like Rick Ross and Kodak Black, plus the...

Continue Reading
Ensign Group Faces Securities Fraud Lawsuit Amid Scandal

Updated Category News Views 0

Ensign's Legal Storm: Investors on Edge Man, you can't ignore the weighty allegations pounding on Ensign Group's door right now. The skilled nursing giant, under the ticker NASDAQ:ENSG, is feeling the heat from a securities class action filed against them, and my gut tells me this isn't going to blow over quietly. This case sure looks like a financial tempest that could...

Continue Reading
Revamp Preschool Questions for Richer Conversations

Updated Category News Views 139

Preschoolers, those tiny agents of chaos, come home with stories that you'd need a magnifying glass to find. Ask 'em "How was school?" and you're met with blank stares or a one-liner. Tami Nix of Archway Academy has been at this game for over 40 years, and she's got a trick or six up her sleeve. Ditch the Generic: Get Specific Yep, those generic questions are about as...

Continue Reading
Commvault's Q2 Fiscal 2027 Shines Bright Amid Complexity

Updated Category News Views 0

Finding Stability in a Shifting Tech Landscape It doesn’t take a crystal ball to see that Commvault is navigating the whirlwind of tech innovation with some serious flair. Their latest quarterly earnings report for Q2 fiscal 2027 is a testament to the rising demand they're experiencing in a world where data protection and resilience are more than just buzzwords. Diving...

Continue Reading
Evaluating PT and OT Benefits: What’s Driving Outcomes?

Updated Category News Views 0

Shifting Gears: Rethinking PT and OT Benefits With an uptick in conversations around physical therapy (PT) and occupational therapy (OT) benefits, it's time for health plans and employers to step up their game. Let's face it: we're not just treating aches and pains anymore. We're dealing with the big picture here - helping folks get back to their daily grind effectively...

Continue Reading
CSQR Faces Scrutiny Over Cash Flow Discrepancies

Updated Category News Views 73

Dalrymple's Short Report Shakes Csquare's Core Csquare, Inc. (NYSE: CSQR) is reeling from a one-two punch: a damning short report by Dalrymple Finance and an 11.8% share tumble. The timing of this financial body blow, coinciding with Csquare's discordant cash flow claims, could mark the beginning of a long battle for investor trust. This ain't the first time the markets...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for DexCom Shareholders: Class Action Filed

Updated Category News Views 165

Class Action Lawsuit for DexCom, Inc. Investors Attention to all DexCom, Inc. investors: a significant class action lawsuit has been initiated for individuals facing substantial losses. The firm Bronstein, Gewirtz & Grossman, LLC has stepped forward, highlighting the opportunity for affected shareholders to take action. Understanding the Class Action This legal action is...

Continue Reading
Fly-E Group Faces Class Action Lawsuit Amid Investor Concerns

Updated Category News Views 180

Understanding the Fly-E Group Class Action Lawsuit Investors should be informed about the recent developments surrounding Fly-E Group, Inc. (NASDAQ: FLYE). A class action lawsuit has emerged, indicating a serious concern regarding the company’s financial and operational transparency. This opportunity is vital for investors who have experienced significant losses. Class...

Continue Reading
Torram Forms Alliance with Blockchain Founders Fund for DeFi

Updated Category News Views 150

Torram Collaborates with Blockchain Founders Fund Torram is thrilled to announce a significant partnership with Blockchain Founders Fund, a distinguished player in the world of blockchain investments. This alliance aims to foster financial technology innovation and maximize the potential of Bitcoin for institutional decentralized finance (DeFi). Unlocking Bitcoin's...

Continue Reading
RS Group Reports Major Advancements in ESG Commitment

Updated Category News Views 141

RS Group's ESG Report Reflects Commitment and Progress In an exciting update that marks a crucial point on its path to sustainability, RS Group's recent ESG report illustrates impressive advances tailored to ensure long-term value for all stakeholders. This latest report, part of their ESG action plan for 2030, allows a clear view of how they are integrating their...

Continue Reading
Investors Alert: Join the FCX Class Action Lawsuit Now

Updated Category News Views 85

Important Notice for Freeport-McMoRan Inc. Shareholders Freeport-McMoRan Inc. (NYSE: FCX) has come under scrutiny, prompting significant discussions among investors. If you've purchased shares in this company during the specified class period, it's essential to stay informed and take necessary action. Understanding the Allegations Against Freeport-McMoRan Inc. Recent...

Continue Reading